Neutral
Our verdict — HC Wainwright & Co. ranks #24 of 65 in our leaderboard: 46.1% hit rate across all stocks, 22% average gain per call, +6 pts vs its sector.
BioMarin Pharmaceutical (BMRN) price target — analyst by analyst
BioMarin Pharmaceutical · Health Care · ref. ETF XLV · price $54.38
By Rédaction JPI Invest · updated
In short — 13 price targets published on BioMarin Pharmaceutical over 90 days: 9 bullish, 0 bearish (69% positive), median target $90. The highest-ranked firm to weigh in is Canaccord Genuity (rank 10, 64.5% hit rate). For each call below we show the firm's real track record — not just its opinion.
The last 13 analyst calls on BMRN
Newest first. The "verdict" is our read on the firm, based on its past calls replayed against actual prices.
Bullish
Our verdict — Piper Sandler ranks #26 of 65 in our leaderboard: 62% hit rate across all stocks, 19.9% average gain per call, +5 pts vs its sector.
Bullish
Our verdict — Jefferies ranks #31 of 65 in our leaderboard: 63.1% hit rate across all stocks, 16.8% average gain per call, +5 pts vs its sector.
Neutral
Our verdict — HC Wainwright & Co. ranks #24 of 65 in our leaderboard: 46.1% hit rate across all stocks, 22% average gain per call, +6 pts vs its sector.
Bullish
Our verdict — BMO Capital ranks #42 of 65 in our leaderboard: 65% hit rate across all stocks, 14.9% average gain per call, +3 pts vs its sector.
Neutral
Our verdict — HC Wainwright & Co. ranks #24 of 65 in our leaderboard: 46.1% hit rate across all stocks, 22% average gain per call, +6 pts vs its sector.
Bullish
Our verdict — Piper Sandler ranks #26 of 65 in our leaderboard: 62% hit rate across all stocks, 19.9% average gain per call, +5 pts vs its sector.
Bullish
Our verdict — Barclays ranks #51 of 65 in our leaderboard: 59.4% hit rate across all stocks, 10.9% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — Canaccord Genuity ranks #10 of 65 in our leaderboard: 64.5% hit rate across all stocks, 28.2% average gain per call, +11 pts vs its sector.
Bullish
Our verdict — Morgan Stanley ranks #48 of 65 in our leaderboard: 61.2% hit rate across all stocks, 12.5% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — Oppenheimer ranks #29 of 65 in our leaderboard: 66.3% hit rate across all stocks, 20.5% average gain per call, +5 pts vs its sector.
Neutral
Our verdict — HC Wainwright & Co. ranks #24 of 65 in our leaderboard: 46.1% hit rate across all stocks, 22% average gain per call, +6 pts vs its sector.
Bullish
Our verdict — Citigroup ranks #22 of 65 in our leaderboard: 65.6% hit rate across all stocks, 21.6% average gain per call, +6 pts vs its sector.
⚠️ Price targets as published by the firms, timestamped at their publication date. The upside shown is vs the price on the day of the call, not today's price. Informational data, not investment advice.
Frequently asked questions
What are analysts saying about BMRN right now?
Over the last 90 days, 13 price targets were published on BioMarin Pharmaceutical: 9 bullish and 0 bearish (69% positive). The median target is $90. The latest call is from September 10, 2026.
Should you trust these price targets?
Not blindly — that's the point of this page: next to each call we show the firm's real track record — its rank among 65 tracked firms, its hit rate and its average gain per call. An ambitious target from a firm that is wrong 6 times out of 10 is not worth the same as one from a consistent firm.
Which firm covering BMRN is the most reliable?
Among the firms that published on BioMarin Pharmaceutical in the last 90 days, our highest-ranked is Canaccord Genuity (rank 10 of 65, 64.5% hit rate, 28.2% average gain per call).
Where does this data come from?
From analyst price targets, timestamped at publication then replayed against the actual price. Firm rankings come from our analyst leaderboard. Updated daily.
💬 A question about BioMarin Pharmaceutical? The JPI assistant answers using our backtest data.
Keep exploring BioMarin Pharmaceutical